Ceftazidime

Ceftazidime is a broad-spectrum cephalosporin antibiotic, specifically a third-generation cephalosporin. It is a semi-synthetic antibiotic derived from cephalosporin C, which is naturally produced by the fungus Acremonium chrysogenum. Ceftazidime is effective against a wide range of gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Haemophilus influenzae.
Ceftazidime is used primarily to treat serious bacterial infections caused by susceptible gram-negative bacteria. Some common indications for its use include lower respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and skin structure infections, bone and joint infections, and septicemia. Ceftazidime may also be used as part of combination therapy for complicated infections of the central nervous system.
The antibacterial activity of Ceftazidime is attributed to its ability to inhibit bacterial cell wall synthesis, specifically the cross-linking of peptidoglycan strands. This process results in the weakening of the bacterial cell wall, ultimately leading to cell death.
Ceftazidime is available in both intravenous and intramuscular formulations, allowing for flexibility in its administration. The dosing regimen depends on the severity of the infection, the patient’s age, weight, and renal function. Monitoring of renal function and adjustment of the dosing regimen are crucial to prevent the accumulation of the drug and its potential toxic effects on the kidneys.